Preclinical and clinical strategies for development of telomerase and telomere inhibitors

S. Sharma, E. Raymond, H. Soda, Daekyu Sun, S. G. Hilsenbeck, A. Sharma, E. Izbicka, B. Windle, D. D. Von Hoff

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background: Telomerase is an important enzyme whose activity has been convincingly demonstrated in humans recently. It is required for maintenance of ends of chromosomes (telomeres) during cell division. Since its presence has been selectively demonstrated in dividing cells including tumor cells, it has generated considerable excitement as a potential anti-cancer strategy. Design: In this article, we review the current relevant biology of the enzyme, the challenges encountered in the preclinical phase of target development and the current efforts that focus on telomeres and telomerase as therapeutic targets. We also speculate on the potential toxicities and mechanisms of resistance that may be encountered during use of such therapies.

Original languageEnglish (US)
Pages (from-to)1063-1074
Number of pages12
JournalAnnals of Oncology
Volume8
Issue number11
DOIs
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Telomerase
Telomere
Enzymes
Cell Division
Neoplasms
Chromosomes
Maintenance
Therapeutics

Keywords

  • Cancer
  • Chemotherapy
  • Telomerase
  • Telomeres

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sharma, S., Raymond, E., Soda, H., Sun, D., Hilsenbeck, S. G., Sharma, A., ... Von Hoff, D. D. (1997). Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Annals of Oncology, 8(11), 1063-1074. https://doi.org/10.1023/A:1008206420505

Preclinical and clinical strategies for development of telomerase and telomere inhibitors. / Sharma, S.; Raymond, E.; Soda, H.; Sun, Daekyu; Hilsenbeck, S. G.; Sharma, A.; Izbicka, E.; Windle, B.; Von Hoff, D. D.

In: Annals of Oncology, Vol. 8, No. 11, 11.1997, p. 1063-1074.

Research output: Contribution to journalArticle

Sharma, S, Raymond, E, Soda, H, Sun, D, Hilsenbeck, SG, Sharma, A, Izbicka, E, Windle, B & Von Hoff, DD 1997, 'Preclinical and clinical strategies for development of telomerase and telomere inhibitors', Annals of Oncology, vol. 8, no. 11, pp. 1063-1074. https://doi.org/10.1023/A:1008206420505
Sharma, S. ; Raymond, E. ; Soda, H. ; Sun, Daekyu ; Hilsenbeck, S. G. ; Sharma, A. ; Izbicka, E. ; Windle, B. ; Von Hoff, D. D. / Preclinical and clinical strategies for development of telomerase and telomere inhibitors. In: Annals of Oncology. 1997 ; Vol. 8, No. 11. pp. 1063-1074.
@article{a2790bdbb47c4ccf8ddfa0d5baefa436,
title = "Preclinical and clinical strategies for development of telomerase and telomere inhibitors",
abstract = "Background: Telomerase is an important enzyme whose activity has been convincingly demonstrated in humans recently. It is required for maintenance of ends of chromosomes (telomeres) during cell division. Since its presence has been selectively demonstrated in dividing cells including tumor cells, it has generated considerable excitement as a potential anti-cancer strategy. Design: In this article, we review the current relevant biology of the enzyme, the challenges encountered in the preclinical phase of target development and the current efforts that focus on telomeres and telomerase as therapeutic targets. We also speculate on the potential toxicities and mechanisms of resistance that may be encountered during use of such therapies.",
keywords = "Cancer, Chemotherapy, Telomerase, Telomeres",
author = "S. Sharma and E. Raymond and H. Soda and Daekyu Sun and Hilsenbeck, {S. G.} and A. Sharma and E. Izbicka and B. Windle and {Von Hoff}, {D. D.}",
year = "1997",
month = "11",
doi = "10.1023/A:1008206420505",
language = "English (US)",
volume = "8",
pages = "1063--1074",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - Preclinical and clinical strategies for development of telomerase and telomere inhibitors

AU - Sharma, S.

AU - Raymond, E.

AU - Soda, H.

AU - Sun, Daekyu

AU - Hilsenbeck, S. G.

AU - Sharma, A.

AU - Izbicka, E.

AU - Windle, B.

AU - Von Hoff, D. D.

PY - 1997/11

Y1 - 1997/11

N2 - Background: Telomerase is an important enzyme whose activity has been convincingly demonstrated in humans recently. It is required for maintenance of ends of chromosomes (telomeres) during cell division. Since its presence has been selectively demonstrated in dividing cells including tumor cells, it has generated considerable excitement as a potential anti-cancer strategy. Design: In this article, we review the current relevant biology of the enzyme, the challenges encountered in the preclinical phase of target development and the current efforts that focus on telomeres and telomerase as therapeutic targets. We also speculate on the potential toxicities and mechanisms of resistance that may be encountered during use of such therapies.

AB - Background: Telomerase is an important enzyme whose activity has been convincingly demonstrated in humans recently. It is required for maintenance of ends of chromosomes (telomeres) during cell division. Since its presence has been selectively demonstrated in dividing cells including tumor cells, it has generated considerable excitement as a potential anti-cancer strategy. Design: In this article, we review the current relevant biology of the enzyme, the challenges encountered in the preclinical phase of target development and the current efforts that focus on telomeres and telomerase as therapeutic targets. We also speculate on the potential toxicities and mechanisms of resistance that may be encountered during use of such therapies.

KW - Cancer

KW - Chemotherapy

KW - Telomerase

KW - Telomeres

UR - http://www.scopus.com/inward/record.url?scp=0030671246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030671246&partnerID=8YFLogxK

U2 - 10.1023/A:1008206420505

DO - 10.1023/A:1008206420505

M3 - Article

C2 - 9426325

AN - SCOPUS:0030671246

VL - 8

SP - 1063

EP - 1074

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -